Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 20/20 | 1.00 |
| ▸ | MMP9 | P14780 | 19/20 | 1.00 |
| ▸ | MMP8 | P22894 | 1/20 | 0.64 |
| ▸ | MMP13 | P45452 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8344261 | 0.90 | MMP2 (0.83) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL5924337 | 0.89 | MMP2 (1.00) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL5924448 | 0.89 | MMP2 (1.00) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL5924550 | 0.83 | MMP2 (0.70) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL8344876 | 0.82 | MMP2 (0.70) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL6591431 | 0.81 | MMP2 (0.82) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL7476592 | 0.80 | MMP2 (0.80) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL6593194 | 0.80 | MMP2 (0.67) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL8337954 | 0.80 | MMP2 (0.81) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL31579683 | 0.78 | MMP2 (0.78) | MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060120956-A1 | Imaging agents comprising barbituric acid derivatives | KOPKA KLAUS | 2006-06-08 | — | — | US | disclosed |
| EP-1549317-A1 | IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES | GE Healthcare Limited (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004032936-A1 | IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES | AMERSHAM PLC (GB) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060120956-A1 | Imaging agents comprising barbituric acid derivatives | CA5A, GABRA5, CA5B | MMP2 4626/4885MMP9 3278/4885MMP8 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.